Chlorzoxazone

Muscle relaxant
  • US DailyMed: Chlorzoxazone
Routes of
administrationBy mouthDrug classSkeletal muscle relaxantsATC code
  • M03BB03 (WHO)
Legal statusLegal status
Pharmacokinetic dataBioavailabilityWell absorbedProtein binding13–18%MetabolismHepaticElimination half-life1.1 hoursDuration of action3–4 hoursExcretionurine (<1%)Identifiers
  • 5-chloro-3H-benzooxazol-2-one
CAS Number
  • 95-25-0 checkY
PubChem CID
  • 2733
IUPHAR/BPS
  • 2322
DrugBank
  • DB00356 checkY
ChemSpider
  • 2632 checkY
UNII
  • H0DE420U8G
KEGG
  • D00771 checkY
ChEBI
  • CHEBI:3655 checkY
ChEMBL
  • ChEMBL1371 checkY
CompTox Dashboard (EPA)
  • DTXSID9022813 Edit this at Wikidata
ECHA InfoCard100.002.186 Edit this at WikidataChemical and physical dataFormulaC7H4ClNO2Molar mass169.56 g·mol−13D model (JSmol)
  • Interactive image
  • Clc2cc1c(OC(=O)N1)cc2
  • InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10) checkY
  • Key:TZFWDZFKRBELIQ-UHFFFAOYSA-N checkY
  (verify)

Chlorzoxazone (INN) is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It can also be administered for acute pain in general and for tension headache (muscle contraction headache). It acts on the spinal cord by depressing reflexes. It is sold under the brand names Lorzone, Paraflex and Muscol and in combination form as Parafon Forte, a combination of chlorzoxazone and acetaminophen (paracetamol). Possible side effects include dizziness, lightheadedness, malaise, nausea, vomiting, and liver dysfunction. When used with acetaminophen it has added risk of hepatotoxicity.[medical citation needed]

It is available as a generic medication.[3]

Like metaxalone, its mechanism of action is still in question. It is believed that metaxalone works by altering serotonin levels and acting as a mild MAO inhibitor.[medical citation needed] The mechanism of action of chlorzoxazone is thought[by whom?] to act on GABAA and GABAB receptors and voltage-gated calcium channels to a degree.[medical citation needed] General central nervous system depression is the only currently accepted aspect to its medical benefits.[medical citation needed] Elucidation of the exact mechanism of action is ongoing but there is limited study due to the existence of more effective, safe muscle relaxants (e.g., diazepam, cyclobenzaprine, tizanidine), greatly limiting the potential benefit of identifying novel compounds which share chlorzoxazone's mechanism of action.

See also

References

  1. ^ "Parafon DSC- chlorzoxazone tablet". DailyMed. 9 February 2010. Retrieved 5 November 2020.
  2. ^ "Lorzone- chlorzoxazone tablet". DailyMed. 21 June 2019. Retrieved 5 November 2020.
  3. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

Further reading

  • Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF (2006). "Chlorzoxazone inhibit contraction of rat thoracic aorta". Eur J Pharmacol. 545 (2–3): 161–6. doi:10.1016/j.ejphar.2006.06.063. PMID 16859676.
  • Park J, Kim K, Park P, Ha J (2006). "Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe". J Clin Pharmacol. 46 (1): 109–14. doi:10.1177/0091270005282635. PMID 16397290. S2CID 20092326.
  • Wan J, Ernstgård L, Song B, Shoaf S (2006). "Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats". J Pharm Pharmacol. 58 (1): 51–61. doi:10.1211/jpp.58.1.0007. PMC 1388188. PMID 16393464.

External links

  • "Chlorzoxazone". Drug Information Portal. U.S. National Library of Medicine.
  • Chloroxazone Safety Data Sheet Archived 2019-07-12 at the Wayback Machine
  • D.F. Marsh, U.S. patent 2,895,877 (1959)
  • v
  • t
  • e
Peripherally acting
(primarily antinicotinic,
NMJ block)
Non-depolarizing
Curare alkaloids
4° ammonium agents
Depolarizing
ACh release inhibitors
Centrally acting
Carbamic acid esters
Benzodiazepines
Nonbenzodiazepines
Thienodiazepines
Quinazolines
Anticholinergics
(Antimuscarinics)
Other
Directly acting
  • v
  • t
  • e
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
  • GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
KCaTooltip Calcium-activated potassium channel
Blockers
  • BKCa-specific: Ethanol (alcohol)
  • GAL-021
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
  • Solnatide
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
  • See here instead.
LGICsTooltip Ligand gated ion channels
  • See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
Portal:
  • icon Medicine


Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e